GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine ...

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...

The US Food and Drug Administration (FDA) announced a forthcoming public advisory committee meeting (AdCom) of the Oncologic Drugs Advisory Committee to review GSK’s marketing application for Blenrep ...

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

By the time her cancer was caught, six months after her symptoms began and two days after her 46th birthday, Louise Greenbank ...

A world-first blood cancer therapy called belantamab mafodotin (Blenrep) is now available on the NHS in England for multiple ...

Copyright: © 2022 Elsevier Ltd. All rights reserved.

Blood cancer patients in England and Wales will be among the first in the world to have access to a new “Trojan horse” treatment. Blenrep has been approved by the National Institute for Health and ...

The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest.

London Tech Week has wrapped for 2025. For a look at this year’s highlights, we’re joined by the Standard’s technology editor, Alex Pell, who not only attended the event but also joined multiple ...

The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending GSK’s Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for ...